类风湿关节炎患者皮质醇的昼夜分泌与治疗反应预测:一项为期6个月的真实世界前瞻性队列研究
该前瞻性队列研究纳入28例中高度活动类风湿关节炎(RA)患者,采用电化学发光免疫法检测基线及治疗3、6个月后的昼夜皮质醇分泌,并以28例COVID-19患者和28例年龄匹配健康对照进行比较。结果显示RA患者唾液皮质醇昼夜分泌与健康对照相似,但低于COVID-19患者;基线晨皮质醇<13.9 nmol/L可预测6个月未达到最小疾病活动度(MDA),灵敏度75%、特异度92%。作者认为RA存在肾上腺储备受损,需进一步研究证实昼夜皮质醇检测对指导治疗决策或预测治疗反应的价值。
要点
- RA患者唾液昼夜皮质醇与健康对照相似,尽管血清CRP高12倍;低于CRP同样高的COVID-19患者(曲线下面积87.0±37.6 vs 146.7±14.3,p<0.001)。
- 基线昼夜皮质醇节律紊乱见于28例RA中15例,健康对照4/28,COVID-19患者20/28。
- 基线晨皮质醇<13.9 nmol/L预测6个月未达MDA:灵敏度75%、特异度92%、p=0.006。
核心结论
- RA患者存在肾上腺储备受损,表现为相对于慢性炎症需求而言皮质醇分泌不足。
- 作者认为需进一步研究证实昼夜皮质醇检测可能有助于指导治疗决策和/或预测RA治疗反应。
研究设计与样本
- 为期6个月的真实世界前瞻性队列研究,纳入28例连续的中度/高度活动RA患者,在基线及治疗起始或升级后3个月和6个月检测昼夜皮质醇(08-12:00/18:00-22:00,电化学发光免疫法)。
- 对照包括28例COVID-19患者和28例年龄匹配的健康个体(HC)。
- 试验注册号NCT05671627。
主要发现
- RA患者唾液昼夜皮质醇与HC相似,尽管血清CRP水平高12倍,且低于COVID-19患者(曲线下面积:RA 87.0±37.6 vs COVID-19 146.7±14.3,p<0.001),后者CRP同样高。
- 基线昼夜皮质醇节律紊乱见于28例RA中15例 vs 28例HC中4例和28例COVID-19患者中20例。
- 6个月时28例中16例达到治疗诱导的最小疾病活动度(MDA)。
- 基线时未达MDA者与达到MDA者人口学和临床特征相当,但未达MDA者基线晨皮质醇更低(10.9±4.0 vs 18.4±8.2 nmol/L,p=0.005)、ACTH更高(4.8±3.3 vs 2.4±0.4 pmol/L,p=0.047)。
- 基线晨皮质醇<13.9 nmol/L预测6个月未达MDA(灵敏度75%、特异度92%、p=0.006);前瞻性测量显示个体化昼夜皮质醇从基线至3个月和6个月基本不变。
关键数值与推荐
- 基线晨皮质醇<13.9 nmol/L预测6个月未达MDA,灵敏度75%、特异度92%、p=0.006。
- 6个月MDA达成:28例中16例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出需进一步研究证实昼夜皮质醇检测可能有助于指导治疗决策和/或预测RA治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: A reduced adrenal reserve-associated cortisol production relative to the enhanced needs of chronic inflammation (disproportion principle) has been observed in rheumatoid arthritis (RA). We examined the possible clinical value of diurnal cortisol measurements in active RA on treatment response prediction. METHODS: Diurnal cortisol production (measured at: 08-12:00/18:00-22:00) was assessed by electrochemiluminescence immunoassay in 28 consecutive patients with moderately/highly active RA, as well as 3 and 6 months after treatment initiation or/escalation. Twenty-eight COVID-19 patients and 28 age-matched healthy individuals (HC) served as controls. RESULTS: Saliva diurnal cortisol production in patients with RA was similar to that of HC, despite 12-fold higher serum C reactive protein (CRP) levels, and lower than COVID-19 patients (area under the curve: RA: 87.0±37.6 vs COVID-19: 146.7±14.3, p<0.001), having similarly high CRP. Moreover, a disturbed circadian cortisol rhythm at baseline was evident in 15 of 28 of patients with RA vs 4 of 28 and 20 of 28 of HC and COVID-19 patients, respectively. Treatment-induced minimal disease activity (MDA) at 6 months was achieved by 16 of 28 patients. Despite comparable demographics and clinical characteristics at baseline, non-MDA patients had lower baseline morning cortisol and higher adrenocorticotropic hormone (ACTH) levels compared with patients on MDA (cortisol: 10.9±4.0 vs 18.4±8.2 nmol/L, respectively, p=0.005 and ACTH: 4.8±3.3 vs 2.4±0.4 pmol/L, respectively, p=0.047). Baseline morning cortisol <13.9 nmol/L predicted non-MDA at 6 months (75% sensitivity, 92% specificity, p=0.006). Prospective measurements revealed that individualised diurnal cortisol production remained largely unchanged from baseline to 3 and 6 months. CONCLUSIONS: An impaired adrenal reserve is present in patients with RA. Further studies to confirm that assessment of diurnal cortisol production may be useful in guiding treatment decisions and/or predicting treatment response in RA are warranted. TRIAL REGISTRATION NUMBER: NCT05671627.
引用
- Yavropoulou MP, Filippa MG, Vlachogiannis NI, et al. Diurnal production of cortisol and prediction of treatment response in rheumatoid arthritis: a 6-month, real-life prospective cohort study. RMD Open. 2024. PMID: 38233075. doi:10.1136/rmdopen-2023-003575
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。